CI

At a glance

ClinicalIndex Comparison Record
Phase 2Not Yet Recruiting· 69 target
Drug / intervention
Golidocitinib +2 moredrug
Likely dose
Sintilimab 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06198907
NCT06198907Phase 2Not Yet Recruiting
CompareCT.gov

A Phase 2, Open-label, Single Arm Study to Investigate the Safety and Efficiency of Golidocitinib in Combination With Sintilimab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With PD-L1TPS ≥ 1%)

Cancer Institute and Hospital, Chinese Academy of Medical Sciences·interventional·Posted Jan 10, 2024·Updated Jan 10, 2024

In Brief

A Phase 2 clinical trial evaluating Golidocitinib, Sintilimab, and 1 other intervention for Non-Small-Cell Lung Cancer. Not yet recruiting, targeting 69 participants across 1 site.

Detailed Summary

This is a phase 2 Study to investigate the safety, tolerability, and anti-tumor activity of golidocitinib in combination with sintilimab as the front-line treatment for patients with metastatic PD-L1 positive non-small cell lung cancer (NSCLC)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small-Cell Lung Cancer
CountriesChina
CollaboratorsDizal Pharmaceuticals

Timeline

Phase 2Not Yet Recruiting
20242025202620272028
First PostedJan 10, 2024
Enrollment StartJan 1, 2024
Primary CompletionDec 1, 2026
Study CompletionDec 1, 2027
TodayJul 1, 2026
Enrollment to primary: 2.9 yearsPosted 2.5 years agoPrimary completion in 5 months

Interventions

Golidocitinibdrug

Daily dosing of golidocitinib

Sintilimabdrug

Sintilimab, 200mg, intravenous, every 3 weeks.

platinum doublet chemotherapydrug

Pemetrexed or nab-paclitaxel +carboplatin, intravenous, every 3 weeks for 2 cycles